MedPath

Effects of Eldecalcitol and Raloxifene on the suppression of new vertebral fracture with osteoporosis in perimenopausal women or ovariectomy patients: Randomized controlled trial

Not Applicable
Recruiting
Conditions
osteoporosis in perimenopausal women or ovariectomy patients
Registration Number
JPRN-UMIN000009378
Lead Sponsor
Tokyo Women's Medical University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
360
Inclusion Criteria

Not provided

Exclusion Criteria

1,If the disease has progressed apparently. 2,If the patient is no longer any reason to visit. 3,Others, If the patient wishes to have the discontinuation of treatment with this protocol. or If the doctor determines that difficult to continue treatment with this protocol.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary end point is incident of new vertebral fractures.
Secondary Outcome Measures
NameTimeMethod
The secondary end points included the changes in bone mineral density of lumbar spine (L2-L4 BMD) and changes in bone turnover markers (tartrate resistant acid phosphatase-5b (TRACP5b), bone-alkaline phosphatase (BAP)).
© Copyright 2025. All Rights Reserved by MedPath